Update on the Pharmacological Treatment of Alzheimers Disease
نویسندگان
چکیده
منابع مشابه
Update on the Pharmacological Treatment of Alzheimer’s Disease
Alzheimer's disease (AD) is the most common neurodegenerative disorder. Worldwide prevalence of the disease is estimated at more than 24 million cases. With aging of populations, this number will likely increase to more than 80 million cases by the year 2040. The annual incidence worldwide is estimated at 4.6 million cases which is the equivalent of one new case every seven seconds! The pathoph...
متن کاملProgress update: Pharmacological treatment of Alzheimer’s disease
A number of drugs have been approved for the treatment of Alzheimer's disease (AD) and a larger number are being studied as possible therapies. The current mainstays of the pharmacotherapy of AD are the cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. They collectively have acceptable tolerability and proven but modest efficacy. The agents being studied include di...
متن کاملGlucose Role in Treatment of Alzheimers’ Disease
1. Dong H, Csernansky JG (2009) Effects of Stress and Stress Hormones on Amyloidβ Protein and Plaque Deposition. J Alzheimers Dis 18: 459-469. 2. Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, et al. (2006) Plasma cortisol and progression of dementia in subjects with Alzheimer‐ type dementia. Am J Psychiatry 163: 2164-2169. 3. Swaab DF, Raadsheer FC, Endert E, Hofman MA, Kamphorst W, et al. ...
متن کاملUpdate on the Pharmacological Treatment of Pathological Gambling.
This is an update to a previously published article discussing the neuropsychopharmacology of pathological gambling (PG) (1). In the prior manuscript, we described how cortico-limbic circuitry and neurotransmitter systems (norepinephrine, serotonin, dopamine, opioids, glutamate, and gamma-aminobutyric acid (GABA)) have been implicated in PG. These systems represent potential targets for psychop...
متن کاملUpdate on the Pharmacological Treatment of Chronic Migraine.
Chronic migraine (CM) is a common and disabling disorder that remains underdiagnosed and poorly treated. Significant unmet therapeutic needs add to the burden of this disorder; even when CM is recognized, effective treatment options are limited and randomized controlled trials supporting the use of various preventive medications are sparse. In this review, we discuss the available options for C...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Neuropharmacology
سال: 2010
ISSN: 1570-159X
DOI: 10.2174/157015910790909520